International Markets for Vascular Access Site Closure Devices — June 2016
International Markets for Vascular Access Site Closure Devices — June 2016
$4,750.00
Cardiovascular diseases (CVDs) are the leading causes of death throughout the world. Based on Datamonitor Healthcare estimates, approximately 500 million CVD-related cases occurred in the United States (U.S.), China, Japan, and the five major countries of Europe (France, Germany, Italy, Spain, and the United Kingdom [U.K.]).
Publisher: Meddevicetracker
- Description
- Contents
- Samples
Cardiovascular diseases (CVDs) are the leading causes of death throughout the world. Based on Datamonitor Healthcare estimates, approximately 500 million CVD-related cases occurred in the United States (U.S.), China, Japan, and the five major countries of Europe (France, Germany, Italy, Spain, and the United Kingdom [U.K.]). According to the World Health Organization, approximately 17 million people die from cardiovascular diseases (CVDs) every year, with over 75% of all CVD-related deaths occurring in low- and middle-income countries. The number of global CVD-related procedures (diagnostic and therapeutic) continues to increase as more people around the world gain access to improved therapies for the diagnosis and management of CVDs. The creation of an arteriotomy, or access site, in the vasculature is central to all interventional cardiology procedures. Post-procedure, the risk of bleeding and/or complications at the vascular access site becomes a major obstacle to early patient discharge. Vascular access site closure devices, or vascular closure devices (VCDs), are utilized to achieve hemostasis and prevent complications (e.g., bleeding and hematoma formation). Over the next five years, the global market for VCDs is expected to experience high, single digit annual growth. By 2020, the total sales attributable to VCDs are anticipated to exceed $1.3 billion globally.
For the purpose of this analysis, region/country-specific market and competitive analyses will focus on the United States (U.S.), Europe, Japan, and the Rest of the world (RoW). The U.S. remains the largest market in terms of total VCD sales, followed by Europe and Asia-Pacific.
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i. Methodology……………………………………………………………………….. ES-2
Exhibit ES-1: Global Vascular Closure Devices Market, Share by Country/Region, 2015 and 2020…………………………………………….. ES-3
1. CARDIOVASCULAR/PERIPHERAL VASCULAR DISEASE OVERVIEW . 1-1
1.1 Selected Cardiovascular Diseases/Disorders……………………………… 1-2
1.1.1 Coronary Heart Disease……………………………………………. 1-2
1.1.1.1 Atherosclerosis………………………………………….. 1-4
1.1.1.2 Angina Pectoris …………………………………………. 1-4
1.1.1.3 Myocardial Infarction ………………………………….. 1-5
1.1.2 Hypertension …………………………………………………………. 1-11
1.1.3 Cardiomyopathy …………………………………………………….. 1-11
1.1.4 Congenital Heart Defects ………………………………………… 1-14
1.1.5 Heart Failure………………………………………………………….. 1-18
1.2 Selected Peripheral Vascular Diseases/Disorders …………………….. 1-19
1.2.1 Peripheral Artery Disease………………………………………… 1-23
1.2.2 Aneurysm ……………………………………………………………… 1-26
1.2.3 Deep Vein Thrombosis and Pulmonary Embolism ………. 1-28
1.2.4 Chronic Venous Insufficiency …………………………………… 1-31
Exhibit 1-1: Statistics for Selected Coronary Heart Disease Risk Factors………… 1-3
Exhibit 1-2: Angina Pectoris, Selected Statistics ………………………………………….. 1-6
Exhibit 1-3: Clinical Classification of AMI …………………………………………………… 1-8
Exhibit 1-4: Myocardial Infarction, Selected Statistics …………………………………… 1-9
Exhibit 1-5: Estimated Incidence Rates for Myocardial Infarction, Select Countries …………………………………………………………………… 1-10
Exhibit 1-6: Hypertension, Selected Statistics ……………………………………………. 1-12
Exhibit 1-7: Estimated Prevalence Rates for Hypertension, Select Countries…. 1-13
Exhibit 1-8: Cardiomyopathy, Selected Statistics ……………………………………….. 1-15
Exhibit 1-9: Congenital Heart Defects, Selected Statistics …………………………… 1-17
Exhibit 1-10: Summary, American College of Cardiology/American Heart
Association Heart Failure Staging System ……………………………….. 1-20
Exhibit 1-11: Heart Failure, Selected Statistics ……………………………………………. 1-21
Exhibit 1-12: Estimated Prevalence Rates for Chronic Heart Failure, Select Countries …………………………………………………………………… 1-22
Exhibit 1-13: Peripheral Artery Disease, Selected Statistics ………………………….. 1-25
Exhibit 1-14: Aortic Aneurysm, Selected Statistics……………………………………….. 1-29
Exhibit 1-15: Deep Vein Thrombosis, Selected Statistics………………………………. 1-32
Exhibit 1-16: Classification of Chronic Venous Insuffiency…………………………….. 1-33
Exhibit 1-17: Chronic Venous Insufficiency, Selected Statistics ……………………… 1-35
2. VASCULAR ACCESS SITE CLOSURE DEVICES ………………………………. 2-1
2.1 Technologies …………………………………………………………………………. 2-2
2.2 Complications………………………………………………………………………… 2-3
2.3 Products ……………………………………………………………………………….. 2-5
Exhibit 2-1: Collagen Plug-based Vascular Closure Devices/St. Jude Medical’s Angio-Seal Evolution ………………………………………………… 2-6
Exhibit 2-2: Gelfoam/Sealant-based Vascular Closure Devices/ Cordis’s ExoSeal ……………………………………………………………………. 2-7
Exhibit 2-3: Selected Images of Hemostatic Patches ……………………………………. 2-8
Exhibit 2-4: Hybrid Vascular Closure Devices/Cardinal Health’s MYNX ACE …… 2-9
Exhibit 2-5: Staple/Clip-based Vascular Closure Devices/Abbott Vascular’s Perclose ProGlide and StarClose SE ………………………………………. 2-10
Exhibit 2-6: Selected Images of External Hemostatic Devices ……………………… 2-11
3. GLOBAL MARKETS FOR VASCULAR ACCESS SITE MANAGEMENT DEVICES ……………………………………………………………………………………….. 3-1
3.1 Global Competitors…………………………………………………………………. 3-3
3.2 Market Forecast: United States ………………………………………………. 3-14
3.2.1 Competitors …………………………………………………………… 3-17
3.3 Market Forecast: Europe……………………………………………………….. 3-19
3.3.1 Competitors …………………………………………………………… 3-24
3.4 Market Forecast: Japan…………………………………………………………. 3-26
3.4.1 Competitors …………………………………………………………… 3-29
3.5 Market Forecast: Rest of the World…………………………………………. 3-31
3.5.1 Competitors …………………………………………………………… 3-35
Exhibit 3-1: Cardiovascular Disease Cases by Country/Region, Combined Caseloads, 2015-2020 ……………………………………………………………. 3-2
Exhibit 3-2: Global Vascular Closure Devices, Market Forecast, 2015-2020 ……. 3-4
Exhibit 3-3: Global Vascular Closure Devices Sales by Country/Region, Combined Market Forecast, 2015-2020 …………………………………….. 3-5
Exhibit 3-4: 2015, Global Vascular Closure Devices Market, Share by Country/Region ……………………………………………………………………… 3-7
Exhibit 3-5: 2015, Global Vascular Closure Devices Market, Share by Supplier…………………………………………………………………. 3-15
Exhibit 3-6: United States Vascular Closure Devices, Market Forecast, 2015-2020 …………………………………………………………….. 3-18
Exhibit 3-7: 2015, United States Vascular Closure Devices Market, Share by Supplier…………………………………………………………………. 3-20
Exhibit 3-8: 2013, Selected Healthcare Statistics for Select European Countries………………………………………………………………. 3-21
Exhibit 3-9: European Vascular Closure Devices, Market Forecast, 2015-2020 …………………………………………………………….. 3-25
Exhibit 3-10: 2015, European Vascular Closure Devices Market, Share by Supplier…………………………………………………………………. 3-27
Exhibit 3-11: Japanese Vascular Closure Devices, Market Forecast, 2015-2020 …………………………………………………………….. 3-30
Exhibit 3-12: 2015, Japanese Vascular Closure Devices Market, Share by Supplier…………………………………………………………………. 3-32
Exhibit 3-13: Rest of the World Vascular Closure Devices, Market Forecast, 2015-2020 …………………………………………………………….. 3-36
Exhibit 3-14: 2015, Rest of the World Vascular Closure Devices Market, Share by Supplier…………………………………………………………………. 3-38
APPENDIX: COMPANY LISTING……………………………………………………………… A-1
APPENDIX: BIBLIOGRAPHY…………………………………………………………………… B-1
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Bococizumab 
Sign up to the